Why the study?
Mortality from chronic heart failure has increased, and medical support needs optimization according to functional class following pacemaker implantation.
How does the frequency and dosage of cardiovascular pharmacotherapy change over 1 year after pacemaker implantation in patients with heart failure, depending on functional class?
How does the frequency and dosage of cardiovascular pharmacotherapy change over 1 year after pacemaker implantation in patients with heart failure, depending on functional class?
Pacemaker implantation in heart failure patients requires careful ongoing titration of medical therapy, particularly with increased utilization and dosing of beta-blockers in higher functional classes.
Supports FC-guided beta-blocker titration post-pacemaker; leaves open randomized outcome confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
O. S. Voronenko (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: